Phase II trial of 3-h infusion of paclitaxel in patients with adenocarcinoma of endometrium: Japanese Multicenter Study Group

Gynecologic Oncology

Volumn 94, Issue 2, 2004, Pages 471-476

  Hirai, Yasuo ^a,i   Hasumi, Katsuhiko ^a   Onose, Ryo ^b   Kuramoto, Hiroyuki ^c   Kuzuya, Kazuo ^d   Hatae, Masayuki ^e   Ochiai, Kazunori ^f   Nozawa, Shiro ^g   Noda, Kiichiro ^h  

^a The Japan Foundation   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e Kagoshima City Hospital   (Japan)

^f JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Adverse reaction; Antineoplastic effect; Chemotherapy; Endometrial cancer; Paclitaxel

Indexed keywords

PACLITAXEL;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER GROWTH; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRY EYE; DYSPNEA; ENDOMETRIUM CARCINOMA; ERYTHROPENIA; EVALUATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HOT FLUSH; HUMAN; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL;

EID: 3543083958     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.05.042     Document Type: Article

References (15)

1. Wingo P.A., Tong T., Bolden S. Cancer statistics. CA Cancer J. Clin. 45:1995;8-30
2. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J. Cancer statistics. CA Cancer J. Clin. 53:2003;5-26
3. Japan Society of Obstetrics and Gynecology Report of the committee of gynecological tumors. J. Jpn. Soc. Obstet. Gynecol. 47:1995;177-211. [in Japanese]
4. Japan Society of Obstetrics and Gynecology Report of the committee of gynecological tumors. J. Jpn. Soc. Obstet. Gynecol. 49:1997;41-75. [in Japanese]
5. Japan Society of Obstetrics and Gynecology Report of the committee of gynecological tumors. J. Jpn. Soc. Obstet. Gynecol. 52:2000;1400-1441. [in Japanese]
6. Japan Society of Obstetrics and Gynecology Report of the committee of gynecological tumors. J. Jpn. Soc. Obstet. Gynecol. 54:2001;1527-1572. [in Japanese]
7. Japan Society of Obstetrics and Gynecology Committee of gynecological tumors: the 36th annual report on treatment. J. Jpn. Soc. Obstet. Gynecol. 53:2001;1136-1169. [in Japanese]
8. Hoskins W.J., Perez C.A., Young R.C. Corpus; epithelial tumours. Principles and practice of gynecologic oncology. third ed.:2000;919-959 Lippincott Williams & Wilkins, Philadelphia, PA
9. Lincoln S., Blessing J.A., Lee R.B., Rocereto T.F. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 88:2003;277-281
10. Tamura T., Sasaki Y., Nishiwaki Y., et al. Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. Jpn. J. Cancer Res. 86:1995;1203-1209
11. Corpus uteri. American Joint Committee on Cancer: AJCC cancer staging manual. fifth ed.:1997;195-200 Lippincott-Raven Publishers, Philadelphia (PA)
12. Lissoni A., Zanetta G., Losa G., Gabriele A., Parma G., Mangioni C. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann. Oncol. 7:1996;861-863
13. Woo H.L., Swenerton K.D., Hoskins P.J. Taxol is active in platinum-resistant endometrial adenocarcinoma. Am. J. Oncol. 19:1996;290-291
14. Ball H.G., Blessing J.A., Lentz S.S., Mutch D. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of endometrium: a Gynecologic Oncology Group study. Gynecol. Oncol. 62:1996;278-281
15. Fleming G.F., Brunetto V.L., Mundt A.J. Randomized trial of doxorubicin (DOX) plus cisplatin (CIS) versus DOX plus CIS plus paclitaxel (TAX) in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study. Proc. Am. Soc. Clin. Oncol. 21(807):2002;202a